Roche: We’ve Abandoned Budgets And It’s Liberated Employees

Bill Anderson says Roche has scrapped budgets and improved productivity and re-energized teams. But is it too good to be true?

IV1910_Productivity_505782307_1200.jpg
Roche pursues an unconventional productivity drive

Big pharma is constantly looking for new ways to control its multi-billion dollar budgets and speed up processes across R&D and commercial divisions. How tightly managers have been able to manage these targets has been a key internal metric. But what if one of these huge corporations were to abandon that core competency of controlling costs, and simply did away with budgets altogether?

This is exactly the radical approach Roche has taken in its commercial division, and three years in, the company...

More from Leadership

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.